Patient preferences for treating refractory overactive bladder in the UK

International Urology and Nephrology

Volumn 47, Issue 10, 2015, Pages 1619-1627

  Hashim, Hashim ^a   Beusterien, Kathleen ^b   Bridges, John F P ^c   Amos, Kaitlan ^d   Cardozo, Linda ^e  

^a BRISTOL UROLOGICAL INSTITUTE   (United Kingdom)

^b ORS Health   (United States)

^c JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^d ORS Health   (United States)

^e KING S COLLEGE HOSPITAL   (United Kingdom)

Author keywords

Botox; Onabotulinum toxin A; Patient preferences; Percutaneous tibial nerve stimulation; Refractory OAB treatment; Sacral neuromodulation

Indexed keywords

BOTULINUM TOXIN A; ACETYLCHOLINE RELEASE INHIBITOR;

ADULT; ARTICLE; CROSS-SECTIONAL STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OVERACTIVE BLADDER; PATIENT DECISION MAKING; PATIENT PREFERENCE; PERCUTANEOUS TIBIAL NERVE STIMULATION; SACRAL NERVE STIMULATION; TIBIAL NERVE; TRANSCUTANEOUS NERVE STIMULATION; UNITED KINGDOM; GREAT BRITAIN; HEALTH CARE SURVEY; IMPLANTABLE NEUROSTIMULATOR; LUMBOSACRAL PLEXUS; MIDDLE AGED; PERCEPTION; RETREATMENT; STATISTICS AND NUMERICAL DATA; TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION; URINARY BLADDER, OVERACTIVE;

ACETYLCHOLINE RELEASE INHIBITORS; ADULT; BOTULINUM TOXINS, TYPE A; CROSS-SECTIONAL STUDIES; FEMALE; GREAT BRITAIN; HEALTH CARE SURVEYS; HUMANS; IMPLANTABLE NEUROSTIMULATORS; LUMBOSACRAL PLEXUS; MALE; MIDDLE AGED; PATIENT PREFERENCE; PERCEPTION; RETREATMENT; TIBIAL NERVE; TRANSCUTANEOUS ELECTRIC NERVE STIMULATION; URINARY BLADDER, OVERACTIVE;

EID: 84944150967     PISSN: 03011623     EISSN: 15732584     Source Type: Journal    
DOI: 10.1007/s11255-015-1100-3     Document Type: Article

References (24)

1. Haylen B, de Ridder D, Freeman RM et al (2010) An International Urogynecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction. Int Urogynecol J 21:5–26
2. Link CL, Steers WD, Kusek JW, McKinlay JB (2011) The Association of Adiposity and Overactive Bladder appears to differ by gender: results from the Boston Area Community Health (BACH) Survey. J Urol 185(3):955–963
3. Irwin DE, Kopp ZS, Agatep B, Milsom I, Abrams P (2011) Worldwide prevalence estimates of lower urinary tract symptoms, overactive bladder, urinary incontinence and bladder outlet obstruction. BJU Int 108(7):1132–1138
4. Irwin DE, Milsom I, Hunskaar S et al (2006) Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol 50(6):1306–1314
5. Lee UJ, Scott VC, Rashid R et al (2013) Defining and managing overactive bladder: disagreement among the experts. Urology 81(2):257–262
6. Elterman DS, Chughtai B, Kaplan SA, Barkin J (2013) Tolterodine for the treatment of urge urinary incontinence. Expert Opin Pharmacother 14(14):1987–1991
7. Brubaker L, Gousse A, Sand P et al (2012) Treatment satisfaction and goal attainment with onabotulinumtoxin A in patients with incontinence due to idiopathic OAB. Int Urogynecol J 23(8):1017–1025
8. Schulte- Baukloh H, Weiss C, Stolze T, Sturzebecher B, Knispel HH (2005) Botulinum-A toxin for treatment of overactive bladder without detrusor overactivity: urodynamic outcome and patient satisfaction. Urology 66(1):82–87
9. Levy M et al (2014) Patient defined goals of care in treatment of medication refractory overactive bladder. Neurourol Urodyn 33(2):180
10. Leong RK, Marcelissen TA, Nieman FH, De Bie RA, Van Kerrebroeck PE, De Wachter SG (2011) Satisfaction and patient experience with sacral neuromodulation: results from a single center sample survey. J Urol 185(2):588–592
11. Bauer RM et al (2011) Patient-reported side effects of intradetrusor botulinum toxin type A for idiopathic overactive bladder syndrome. Urol Int 86(1):68–72
12. El-Azab AS, Moeen AM (2013) The satisfaction of patients with refractory idiopathic overactive bladder with onabotulinumtoxinA and augmentation cystoplasty. Arab J Urol 11(4):344–349
13. Imam H (2011) Patient satisfaction after intravesical botulinum toxin type a injection for refractory detrusor overactivity. Neurourol Urodyn 30(2):266
14. Urinary incontinence in women: the management of urinary incontinence in women [Internet], 2nd ed. The Royal College of Obstetricians and Gynaecologists, London 2013 http://www.nice.org.uk/guidance/cg171/resources/cg171-urinary-incontinence-in-women-full-guideline3
15. ® versus sacral neuromodulation for overactive bladder symptoms after unsuccessful anticholinergic treatment. Int Urogynecol J 25(8):1059–1064
16. Rudd I, Kavia R, Jenks J et al (2012) Patient treatment preferences for symptomatic refractory urodynamic idiopathic detrusor overactivity (IDO) [Abstract]. BJU Int 109(Suppl. 7):45
17. Flynn TN (2010) Valuing citizen and patient preferences in health: recent developments in three types of best–worst scaling. Expert Rev Pharmacoecon Outcomes Res 10(3):259–267
18. Bridges J, Kinter E, Schmeding A et al (2011) Can patients diagnosed with schizophrenia complete choice-based conjoint analysis tasks. Patient 4:267–275
19. Umberger W, Stringer R, Mueller SC (2010) Selected paper prepared for presentation at the agricultural & applied economics. Using Best–Worst Scaling to Determine Market Channel Choice by Small Farmers in Indonesia. Association 2010 AAEA, CAES, & WAEA Joint Annual Meeting, Denver, Colorado, 25–27 July 2010
20. IBM Corp. Released (2013) IBM SPSS Statistics for Windows, Version 22.0. Armonk, NY: IBM Corp http://www-01.ibm.com/support/docview.wss?uid=swg21476197
21. Peay HL, Hollin I, Fischer R, Bridges JF (2014) A community-engaged approach to quantifying caregiver preferences for the benefits and risks of emerging therapies for Duchenne muscular dystrophy. Clin Ther 36(5):624–637
22. Reed Johnson F, Van Houtven G, Ozdemir S et al (2009) Multiple sclerosis patients benefit-risk preferences serious adverse event risks versus treatment efficacy. J Neurol 256:554–562
23. Beusterien K, Davies J, Leach M et al (2010) Population preference values for treatment outcomes in chronic lymphocytic leukaemia: a cross-sectional utility study. Health Qual Life Outcomes 8:50
24. Beusterien K, Szabo S, Kotapati S et al (2009) Societal preference values for advanced melanoma health states in the United Kingdom and Australia. Br J Cancer 101(3):387–389